Project Grant R50CA285360
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$136K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Virginia, USA
Similar Awards
This National Cancer Institute (NCI) Project Grant award under CFDA 93.395 "Cancer Treatment Research" provides $196,267 in funding to the University of California, Irvine (UCI) to advance novel cancer prevention and therapeutic strategies across NCI's clinical trial networks. The award will support the Principal Investigator's leadership roles on key NCI committees, completion of an ongoing Phase III clinical trial focused on preventing colorectal adenomas in a racially/ethnically...
This federal Project Grant award for $194,778 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the optimization of strategies to improve NCI-sponsored clinical trial participation across the Weill Cornell Medicine - Meyer Cancer Center sphere, which serves a diverse population of approximately 6 million patients in the New York City metropolitan area. The principal investigator, Dr. Tagawa, has extensive experience leading and mentoring others on NCI clinical...
This $132,015 Project Grant award was provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to The Ohio State University. The funding will support efforts to improve enrollment in clinical trials for gynecologic cancers, especially among underrepresented populations. Key activities include: Developing a comprehensive system at The Ohio State University Comprehensive Cancer Center to streamline molecular matching and identification of patients for...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $415,259 to the Rector & Visitors of the University of Virginia to conduct research on the role of long noncoding RNAs in acute myeloid leukemia (AML). The project aims to 1) determine the role of a specific regulatory RNA in primary and relapsed AML, and 2) define the mechanism underlying its deregulation in AML. This research will provide insights into how noncoding RNAs...
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $159,574 to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) to increase access and participation to early phase clinical trials for underrepresented populations, including veterans. The project aims to develop sustainable strategies to extend access and boost participation in the Experimental Therapeutics Clinical Trials Network (ETCTN) clinical...
This Project Grant award, titled "EXPLOITING THERAPEUTIC VULNERABILITIES IN HEPATOCELLULAR CARCINOMA (ELEVATE)", is funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research). The $2,678,459 award aims to advance the understanding of molecular mechanisms regulating non-alcoholic steatohepatitis (NASH)-associated hepatocellular carcinoma (HCC) and develop novel combinatorial treatment approaches. The award supports four research projects, an administrative core, a...
The National Cancer Institute (NCI) awarded a $226,504 Project Grant (CFDA 93.396 - Cancer Biology Research) to the Rector & Visitors of the University of Virginia (UVA) to elucidate the role of B/T cell-enriched immune aggregates in immune surveillance against triple-negative breast cancer (TNBC). The project aims to study how these novel immune aggregates form and function to control pre-malignant progression of TNBC, which could inform future strategies to enhance immune surveillance...
This $172,197 Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) aims to establish and refine processes to facilitate clinical trials in cancer interception (active cancer prevention) at the University of Kansas Cancer Center (KUCC). Key objectives include: Hiring project navigators to support study approvals for principal investigators in non-oncology departments outside KUCC Training research coordinators in cancer prevention trial processes...
This federal Project Grant award of $130,426 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports the research efforts of Dr. Cathy Eng at Vanderbilt University Medical Center. The award aims to cultivate programmatic efforts to optimize the conduct and implementation of NCI-funded clinical trials, leveraging Dr. Eng's extensive experience and leadership roles within the National Clinical Trials Network (NCTN). Dr. Eng has led the...
This $181,640 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research led by a clinical scientist at The University of Texas MD Anderson Cancer Center. The primary objectives are to: Expand on the role of liquid biopsy biomarkers, specifically circulating tumor DNA (ctDNA) and extravesicle RNA (evRNA), to generate novel combination immunotherapy trials for colorectal and anal cancers. This includes analyzing samples from...